These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

588 related items for PubMed ID: 8988733

  • 1. The influence of prostate volume on the ratio of free to total prostate specific antigen in serum of patients with prostate carcinoma and benign prostate hyperplasia.
    Stephan C, Lein M, Jung K, Schnorr D, Loening SA.
    Cancer; 1997 Jan 01; 79(1):104-9. PubMed ID: 8988733
    [Abstract] [Full Text] [Related]

  • 2. The importance of human glandular kallikrein and its correlation with different prostate specific antigen serum forms in the detection of prostate carcinoma.
    Recker F, Kwiatkowski MK, Piironen T, Pettersson K, Lümmen G, Wernli M, Wiefelspütz J, Graber SF, Goepel M, Huber A, Tscholl R.
    Cancer; 1998 Dec 15; 83(12):2540-7. PubMed ID: 9874461
    [Abstract] [Full Text] [Related]

  • 3. Discrimination of men with prostate cancer from those with benign disease by measurements of human glandular kallikrein 2 (HK2) in serum.
    Becker C, Piironen T, Pettersson K, Björk T, Wojno KJ, Oesterling JE, Lilja H.
    J Urol; 2000 Jan 15; 163(1):311-6. PubMed ID: 10604382
    [Abstract] [Full Text] [Related]

  • 4. IGF-II serum levels increase discrimination between benign prostatic hyperplasia and prostate cancer and improve the predictive value of PSA in clinical staging.
    Trojan L, Bode C, Weiss C, Mayer D, Grobholz R, Alken P, Michel MS.
    Eur Urol; 2006 Feb 15; 49(2):286-92; discussion 292. PubMed ID: 16386354
    [Abstract] [Full Text] [Related]

  • 5. The ratio of free to total serum prostate specific antigen and its use in differential diagnosis of prostate carcinoma in Japan.
    Egawa S, Soh S, Ohori M, Uchida T, Gohji K, Fujii A, Kuwao S, Koshiba K.
    Cancer; 1997 Jan 01; 79(1):90-8. PubMed ID: 8988731
    [Abstract] [Full Text] [Related]

  • 6. [Changes of serum total PSA and free PSA in patients with prostate carcinoma and benign prostate hyperplasia].
    Gao ZW, Liu G, Sheng BW.
    Ai Zheng; 2004 Jun 01; 23(6):701-3. PubMed ID: 15191675
    [Abstract] [Full Text] [Related]

  • 7. Free and total serum PSA values in patients with prostatic intraepithelial neoplasia (PIN), prostate cancer and BPH. Is F/T PSA a potential probe for dormant and manifest cancer?
    Tarle M, Kraljić I.
    Anticancer Res; 1997 Jun 01; 17(3A):1531-4. PubMed ID: 9179191
    [Abstract] [Full Text] [Related]

  • 8. Calculated fast-growing benign prostatic hyperplasia--a risk factor for developing clinical prostate cancer.
    Hammarsten J, Högstedt B.
    Scand J Urol Nephrol; 2002 Jun 01; 36(5):330-8. PubMed ID: 12487736
    [Abstract] [Full Text] [Related]

  • 9. Total and free PSA: a methodical and clinical evaluation of five assays.
    Reiter W, Stieber P, Schmeller N, Nagel D, Hofmann K, Fateh-Moghadam A.
    Anticancer Res; 1997 Jun 01; 17(6D):4759-65. PubMed ID: 9494603
    [Abstract] [Full Text] [Related]

  • 10. Serum levels of prostate-specific antigen and vitamin D in peritoneal dialysis patients.
    Passadakis P, Ersoy F, Tam P, Memmos D, Siamopoulos K, Ozener C, Akçiçek F, Camsari T, Ates K, Ataman R, Vlachojannis J, Dombros N, Utas C, Akpolat T, Bozfakioglu S, Wu GG, Karayaylali I, Arinsoy T, Stathakis C, Yavuz M, Tsakiris D, Dimitriades A, Yilmaz ME, Gültekin M, Karayalçin B, Challa A, Polat N, Oreopoulos DG.
    Adv Perit Dial; 2004 Jun 01; 20():203-8. PubMed ID: 15384827
    [Abstract] [Full Text] [Related]

  • 11. [The role of prostate specific antigen in diagnosis of localized adenocarcinoma of the prostate. Nara Uro-Oncology Research Group].
    Hirao Y, Ozono S, Kagebayashi Y, Yoshi M, Tani Y, Uemura H, Momose H, Okajima E.
    Hinyokika Kiyo; 1996 Oct 01; 42(10):795-804. PubMed ID: 8951478
    [Abstract] [Full Text] [Related]

  • 12. Stability of free and total prostate specific antigen in serum from patients with prostate carcinoma and benign hyperplasia.
    Paus E, Nilsson O, Børmer OP, Fosså SD, Otnes B, Skovlund E.
    J Urol; 1998 May 01; 159(5):1599-605. PubMed ID: 9554362
    [Abstract] [Full Text] [Related]

  • 13. Insulin-like growth factor-binding protein-2 in patients with prostate carcinoma and benign prostatic hyperplasia.
    Ho PJ, Baxter RC.
    Clin Endocrinol (Oxf); 1997 Mar 01; 46(3):333-42. PubMed ID: 9156044
    [Abstract] [Full Text] [Related]

  • 14. Accurate cut-off point for free to total prostate-specific antigen ratio used to improve differentiation of prostate cancer from benign prostate hyperplasia in Iranian population.
    Amirrasouli H, Kazerouni F, Sanadizade M, Sanadizade J, Kamalian N, Jalali M, Rahbar K, Karimi K.
    Urol J; 2010 Jun 10; 7(2):99-104. PubMed ID: 20535696
    [Abstract] [Full Text] [Related]

  • 15. Ratio of alpha 1-antichymotrypsin--prostate specific antigen to total prostate specific antigen in prostate cancer diagnosis.
    Lein M, Jung K, Elgeti U, Brux B, Sinha P, Schnorr D, Loening SA.
    Anticancer Res; 2000 Jun 10; 20(6D):4997-5001. PubMed ID: 11326657
    [Abstract] [Full Text] [Related]

  • 16. Diagnostic validity of macrophage migration inhibitory factor in serum of patients with prostate cancer: a re-evaluation.
    Michael A, Stephan C, Kristiansen G, Burckhardt M, Loening SA, Schnorr D, Jung K.
    Prostate; 2005 Jan 01; 62(1):34-9. PubMed ID: 15389818
    [Abstract] [Full Text] [Related]

  • 17. Diagnostic approach to prostate cancer using total prostate specific antigen-based parameters together.
    Serdar MA, Oguz O, Olgun A, Seçkin B, Ilgan S, Hasimi A, Salih M, Peker F, Kutluay T.
    Ann Clin Lab Sci; 2002 Jan 01; 32(1):22-30. PubMed ID: 11848613
    [Abstract] [Full Text] [Related]

  • 18. Insulin-like growth factor-binding protein-2 in patients with prostate carcinoma and benign prostatic hyperplasia.
    Ho PJ, Baxter RC.
    Clin Endocrinol (Oxf); 1997 Feb 01; 46(2):145-54. PubMed ID: 9135695
    [Abstract] [Full Text] [Related]

  • 19. The effect of high grade prostatic intraepithelial neoplasia on serum total and percentage of free prostate specific antigen levels.
    Ramos CG, Carvahal GF, Mager DE, Haberer B, Catalona WJ.
    J Urol; 1999 Nov 01; 162(5):1587-90. PubMed ID: 10524873
    [Abstract] [Full Text] [Related]

  • 20. Review on the simultaneous determination of total prostate-specific antigen and free prostate-specific antigen.
    van Iersel MP, Witjes WP, Thomas CM, Segers MF, Oosterhof GO, Debruyne FM.
    Prostate Suppl; 1996 Nov 01; 7():48-57. PubMed ID: 8950364
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.